These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

885 related items for PubMed ID: 16438660

  • 1. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
    Song J, Hanniford D, Doucette C, Graham E, Poole MF, Ting A, Sherf B, Harrington J, Brunden K, Stricker-Krongrad A.
    Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
    Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I.
    Eur J Pharmacol; 2008 Oct 10; 594(1-3):32-8. PubMed ID: 18703043
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.
    Canal CE, Morgan D, Felsing D, Kondabolu K, Rowland NE, Robertson KL, Sakhuja R, Booth RG.
    J Pharmacol Exp Ther; 2014 May 10; 349(2):310-8. PubMed ID: 24563531
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.
    Rosenzweig-Lipson S, Zhang J, Mazandarani H, Harrison BL, Sabb A, Sabalski J, Stack G, Welmaker G, Barrett JE, Dunlop J.
    Brain Res; 2006 Feb 16; 1073-1074():240-51. PubMed ID: 16430874
    [Abstract] [Full Text] [Related]

  • 10. High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.
    Fitzgerald LW, Conklin DS, Krause CM, Marshall AP, Patterson JP, Tran DP, Iyer G, Kostich WA, Largent BL, Hartig PR.
    J Neurochem; 1999 May 16; 72(5):2127-34. PubMed ID: 10217294
    [Abstract] [Full Text] [Related]

  • 11. Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands.
    Canal CE, Cordova-Sintjago T, Liu Y, Kim MS, Morgan D, Booth RG.
    J Pharmacol Exp Ther; 2013 Dec 16; 347(3):705-16. PubMed ID: 24080681
    [Abstract] [Full Text] [Related]

  • 12. Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain.
    Appel NM, Mitchell WM, Garlick RK, Glennon RA, Teitler M, De Souza EB.
    J Pharmacol Exp Ther; 1990 Nov 16; 255(2):843-57. PubMed ID: 2243353
    [Abstract] [Full Text] [Related]

  • 13. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
    Borroto-Escuela DO, Romero-Fernandez W, Narvaez M, Oflijan J, Agnati LF, Fuxe K.
    Biochem Biophys Res Commun; 2014 Jan 03; 443(1):278-84. PubMed ID: 24309097
    [Abstract] [Full Text] [Related]

  • 14. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist.
    Dunlop J, Watts SW, Barrett JE, Coupet J, Harrison B, Mazandarani H, Nawoschik S, Pangalos MN, Ramamoorthy S, Schechter L, Smith D, Stack G, Zhang J, Zhang G, Rosenzweig-Lipson S.
    J Pharmacol Exp Ther; 2011 Jun 03; 337(3):673-80. PubMed ID: 21402690
    [Abstract] [Full Text] [Related]

  • 15. Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A/2C agonism.
    Bishop C, Tessmer JL, Ullrich T, Rice KC, Walker PD.
    J Pharmacol Exp Ther; 2004 Aug 03; 310(2):687-94. PubMed ID: 15044557
    [Abstract] [Full Text] [Related]

  • 16. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
    Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L.
    Br J Pharmacol; 2003 Sep 03; 140(2):277-84. PubMed ID: 12970106
    [Abstract] [Full Text] [Related]

  • 17. Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation.
    Wang CD, Gallaher TK, Shih JC.
    Mol Pharmacol; 1993 Jun 03; 43(6):931-40. PubMed ID: 8316224
    [Abstract] [Full Text] [Related]

  • 18. Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs.
    Newton RA, Phipps SL, Flanigan TP, Newberry NR, Carey JE, Kumar C, McDonald B, Chen C, Elliott JM.
    J Neurochem; 1996 Dec 03; 67(6):2521-31. PubMed ID: 8931486
    [Abstract] [Full Text] [Related]

  • 19. Antiallodynic effects of intrathecally administered 5-HT(2C) receptor agonists in rats with nerve injury.
    Obata H, Saito S, Sakurazawa S, Sasaki M, Usui T, Goto F.
    Pain; 2004 Mar 03; 108(1-2):163-9. PubMed ID: 15109520
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological characterisation of human 5-HT2 receptor subtypes.
    Jerman JC, Brough SJ, Gager T, Wood M, Coldwell MC, Smart D, Middlemiss DN.
    Eur J Pharmacol; 2001 Feb 23; 414(1):23-30. PubMed ID: 11230991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.